Quick Answer
PLIANT THERAPEUTICS, INC. reported Stockholders Equity of $181.21 million for the year ending 2025.
- PLIANT THERAPEUTICS, INC. showed a decrease of -40.4% in Stockholders Equity from 2024 to 2025.
- This data is from PLIANT THERAPEUTICS, INC.'s annual report (Form 10-K), filed with the SEC on March 11, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2019: -$86.51 million | Q2 2019: -$102.74 million | Q3 2019: -$116.88 million | Q1 2020: -$64.75 million | Q2 2020: $315.82 million | Q3 2020: $300.35 million | Q1 2021: $264.17 million | Q2 2021: $243.98 million | Q3 2021: $220.44 million | Q1 2022: $173.79 million | Q2 2022: $147.79 million | Q3 2022: $336.99 million | Q1 2023: $561.92 million | Q2 2023: $533.07 million | Q3 2023: $503.05 million | Q1 2024: $437.33 million | Q2 2024: $392.68 million | Q3 2024: $345.82 million | Q1 2025: $257.16 million | Q2 2025: $220.08 million | Q3 2025: $200.31 million.
- Over the full 8 years of available data (2018 to 2025), PLIANT THERAPEUTICS, INC.'s Stockholders Equity has grown by 353.5%.
- Historical annual values: Fiscal year 2025: $181.21 million | Fiscal year 2024: $304.08 million | Fiscal year 2023: $473.58 million | Fiscal year 2022: $313.34 million | Fiscal year 2021: $199.06 million | Fiscal year 2020: $283.06 million | Fiscal year 2019: -$76.30 million | Fiscal year 2018: -$71.47 million.
- Data sourced from SEC EDGAR public filings as of August 4, 2026.
Last verified: